



CORTISOL IN POSTMENOPAUSAL WOMEN WITH DEPRESSION

Medical Science

Pallavi Janrao Kamble

Assistant Professor, Government Medical College, Gondia

Sankalp Kumar Tripathi*

Assistant Professor, Government Medical College, Gondia *Corresponding Author

Vinayak.W. Patil

Professor and HOD, Grant Government Medical College, Mumbai

ABSTRACT

Background-

Women are at a two fold greater risk for developing depression as compared to men. It has been found that women are vulnerable to depression during and after menopausal transition. Alterations in endocrine and metabolic factors including monoamine deficiency, HPA and HPT axis dysfunction and inflammation and neurodegenerative alteration can be responsible for depressive disorder. So the present study was undertaken to find out the total cortisol levels in postmenopausal women with and without depression.

Aims and objectives-

To determine the total cortisol levels in postmenopausal women with and without depression.

Materials and methods-

Fasting blood samples were analyzed for the total Cortisol levels in 30 postmenopausal females suffering from depression and 30 postmenopausal females not suffering from depression by using immunoassay technique.

Results-

Serum Total Cortisol level was significantly higher in Case group (mean-37.90) as compared to Control group (mean-29.65).

Conclusions-

Our findings support the hypothesis that hyperactivation of HPA axis leads to hypercortisolism in postmenopausal women with depression.

KEYWORDS:

HPA-Hypothalamic-Pituitary-adrenaxis,ACTH-Adrenocorticotrophic Hormon

Introduction

Depression is one of the most frequent and debilitating psychiatric disorder[1].The various community based studies conducted in India based on mental disorder found the prevalence rate of depression between 13 to 25%[2], the prevalence rate of depressive disorder between 10 to 20% in elderly population has been estimated by WHO [3]. Majority of depressive disorders remain undiagnosed and untreated because of wrong belief that it is part of aging and is a social stigma.

There is two fold greater risk for developing depression in women as compared to men[4]. Depression occurs in 21% of women over their life time[5]. Various studies found that women are at increased risk of depression during and after menopausal transition[6]. 26-33% of women develop a first episode of depression during the menopausal transition[7,8]. During postmenopausal period the mood disorders are common and women spend 30% of their lives in postmenopausal period. Perez-Lopez et al. studied that 45% women suffered from depression during postmenopausal period[9]. perimenopausal and postmenopausal women had significantly increased risk of having elevated depressive symptoms as compared to premenopausal women has been proved by SWAN study [10].HPT and HPA axis alteration or hyperactivation is responsible for depression has been proved by various studies[11,12]. Any type of stress causes release of CRH from hypothalamus which causes ACTH secretion from corticotrophic cells of anterior pituitary and cortisol from adrenal cortex[13]. Various studies documented increased cortisol secretion in major depression cases[14] while lower cortisol level found in another study[15]. Normal cortisol level also observed in some studies[16]. there is so much inconsistency regarding the cortisol level in depression and also very few studies has been conducted to study cortisol level in postmenopausal women suffering from depression..So the present study was undertaken to find out the total cortisol levels in postmenopausal women with and without depression.

Materials and methods

A complete medical history and informed consent was obtained from all participants included in the study . Diagnosis of depression was done by psychiatrist by using DSM-IV criteria and Assessment of severity of depression was done by 21 items Hamilton rating scale for depression (21itemHRSD)

30 postmenopausal women diagnosed with major depression were enrolled in the study as cases and 30 normal postmenopausal women without any past history of depression were enrolled in the study as controls.

Inclusion Criteria:

1. Postmenopausal women (above 50 years of age) were selected for the study.
2. Subjects without any disorders not receiving or had not received anti-cancer medications or any thyroid drugs.
3. Thirty age matched controls with normal liver, kidney function and thyroid function belonging to the same socioeconomic background were also included as a control group used for comparison with study subjects suffering from depression.

Exclusion Criteria:

1. Postmenopausal women on hormonal treatment.
2. Patients with thyroid and adrenal gland disorder, severe liver diseases, end stage renal diseases, human immune deficiency virus infection, diabetes, hypertension and cancer.
3. Subjects on medications [therapy involving L-T4/T3, thyrostatics (carbimazole, propylthiouracil), steroid, antidepressant agent (S-adenosyl-methionine),antiepileptic agents (carbamazepine, phenytoin), Anticancer agents (6-azauridine, xanthopterin, antifolates, tamoxifen), anticonvulsant agents (GABA), and bronchodilator (theophylline)].

Analysis-**Blood Sample Collection :**

1. 5 ml fasting venous blood sample was collected in plain vacutainer under all aseptic precautions.
2. The samples were kept for 30 minutes for clotting after which they were centrifuged at 3000 rpm for 5 min to obtain clear serum.
3. Serum samples were aliquotted in micro centrifuge tubes and stored at -20°C till further assay.The biochemical parameters to be assayed were stable at said temperature for 6–8 weeks.
4. Serum samples were used for the analysis of cortisol levels and A fully automated enzyme amplified chemiluminescent

immuno assay based Immulite 1000 analyzer was used for analysis

Statistical Analysis :

Numerical variables were reported in terms of mean and standard deviation. An independent sample t-test was used to compare the difference of means. In this analysis, variables showing p-value less than 0.05 were considered to be statistically significant. The SPSS software was used for data analysis.

Results-


Table No. 1 shows Mean Total Cortisol was 37.90 among Case group which was significantly more as compared to 29.65 among Control group.(table.no.1 and figure. No.1)

Table. No.1- COMPARISON OF TOTAL CORTISOL BETWEEN TWO GROUPS

Groups	Mean Total Cortisol ($\bar{x} \pm SD$)
Case	*37.90 09.40
Control	29.65 06.71

By Student t Test

P=0.01, * Significant



(Figure.No.1)

Discussion

Menopause is word developed from Greek root meaning cessation (pauses) and month (men), designing the interruption of monthly blood flow named menstruation. This state is retrospectively fixed, after the absence of menstruation for 12 consecutive months [17]. Menopause is an important period in women life. It has been defined as permanent cessation of menstruation due to failure of ovarian follicular development despite of gonadotropin stimulation. The mean age of menopause is 51yrs, but can vary from 45-55 yrs. Menopause can occur as early as 30's or as late as 60's in rare cases [18]. Women now spend one third to one half of their lives after menopause. Menopausal Status were classified as per the recommendation by the World Health Organization (WHO) and Stages of Reproductive Aging workshop. [19,20].

Menopausal status was based on menstrual bleeding patterns in the previous 12 months and was categorized as

- (1) premenopausal (menstrual period in the past 3 months with no change in regularity in the past 12 months);
- (2) Early perimenopausal (menstrual period in the past 3 months with change in regularity over the previous 12 months);
- (3) Late perimenopausal (no menstrual period within the past 3 months but some menstrual bleeding within the past 12 months); and
- (4) Postmenopausal (no menstrual period within the past 12 months).

Studies has found association between depression and menopausal symptoms women during their menopausal transition suffers from various physiological menopausal symptoms which include somatic, sexual dysfunction and various vasomotor symptoms (like hot flushes and night sweats, vaginal dryness along with acnes and stiffness of joints and trouble in sleeping and lack of energy these symptoms lead to depressed mood in many females during their menopausal transition period [7]. this transition period also associated with extreme hormonal changes but it is also accompanied by changes in personal, professional and family responsibilities, stressful life events and low socioeconomic support, some studies has found depressive symptoms are associated with various health, social and demographic factors [8]

while some studies has proven that risk of depression is independent of health, social and demographic factors [6]

Women during their late stage of menopausal transition has increased risk of depression because of changes in reproductive hormones like increased FSH and LH and testosterone levels along with decreased in estrogen levels [7]

Womens suffered from various physiological menopausal symptoms during and after menopause which is responsible for mental stress and in order to maintain physiological stability the activation HPA axis takes place as an adaptive mechanism [21]. Studies reported that directly or indirectly cortisol plays pathogenic role in depression i.e. by induction or exacerbation of disturbances in monoaminergic transmission [22]. Increased FSH level causes increased secretion of estrogen from ovarian follicle as women approaches menopause and estrogen regulates CRH gene expression so hyperestrogenemia causes increased Cortisol level [23]. CRH release stimulates the synthesis and release of adrenocorticotrophic (ACTH) by the anterior pituitary, which in turn stimulates the synthesis and release of cortisol by the adrenal cortex. our studies have several limitations including that we have not taken into consideration various social and demographic factors and various menopausal symptoms which may be responsible for depressive symptoms though health factors which may affect the cortisol levels has been minimized by excluding the postmenopausal women having any major disorder also with no past history of major depression and those postmenopausal women on any medication or hormonal supplements. Our results revealed that there might be hyperactivation of HPA axis that causing CRH overdrive resulting in hypercortisolemia in postmenopausal women with depression. The study might have proved very useful if we have analysed the FSH, Estrogen and ACTH level along with cortisol levels.

Conclusion-

increased cortisol level because of hyperactivation of HPA Axis is observed in postmenopausal women with depression and it can be used as biological marker for diagnosis of depression in postmenopausal women.

References

1. Gelder M, Mayou R, Geddes J. Oxford Core Text of Psychiatry. 2nded. Oxford:Oxford University Press; 1999.
2. Barua A, Kar N. screening for depression in Indian elderly population. India J Psychiatry .2010; 50 (20):150-1539.
3. Wig NN. World Health Day 2001. India J Psychiatry 2001; 41:3-14.
4. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age of onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:593-602. [PubMed: 15939837].
5. Joseph MC, Erik RV, Carmen AC, Jennifer LM, Joan R, Susan DR, Wayne K. Presenting Symptoms of Women With Depression in an Obstetrics and Gynecology Setting. Obstet Gynecol. 2013 August; 122(2 0 1): 313-318.
6. Joyce TB, Karen A M, Laura LS, Sarah B, Nancy E A, Howard MK, Susan AE et al. Depressive symptoms during the menopausal transition: The Study of Women's Health Across the Nation (SWAN) J Affect Disord. 2007 November; 103(1-3): 267-272.
7. Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormone and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 2006; 63:375-82. [PubMed: 16585466].
8. Bromberger JT, Harlow S, Avis N, Kravitz HM, Cordal A. Racial/ethnic differences in the prevalence of depressive symptoms among middle-aged women: The Study of Women's Health Across the Nation (SWAN). Am J Public Health 2004; 94:1378-85. [PubMed: 15284047].
9. M. Stanislawski, M. Szkup-Jabłońska, A. Jurczak, S. Wieder-Husza et al. The Severity of Depressive Symptoms vs. Serum Mg and Zn Levels in Postmenopausal Women. Biol Trace Elem Res. 2014; 157:30-35.
10. Mary FM, Ellen W F, Hui Lin, Mary DS. Higher DHEA-S (Dehydroepiandrosterone Sulfate) Levels are Associated with Depressive Symptoms during the Menopausal Transition: Results from the PENN Ovarian Aging Study. Arch Womens Ment Health. 2011 October; 14(5): 375-382.
11. Schmidt HD, Shelton RC, Duman RS: Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology, 2011; 36: 2375-94.
12. Kirkegaard C and Faber J. The role of thyroid hormones in depression. European Journal of Endocrinology 1998; 138 1-9: 285-294.
13. Jessop D.S., 1999. Review: central non-glucocorticoid inhibitors of the hypothalamo-pituitary-adrenal axis. J. Endocrinol. 160, 169-180.
14. Deuschle M, Schweiger U, Weber B, Gotthardt U, Korner A, Schmitter J, Standhardt H, Lammers C, Heuser I. Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. j clin endocrinol metab. 1997; 82:234-238 [pubmed: 8989265].
15. Jantien P B, Bente C A, Witte J G H, Jochanan H, Erik E, Cassandra Z, Aart H S, Jan G P T, Richard V D, Wilmar M W and Eric F. Thyroid and adrenal axis in major depression: a controlled study in outpatients. European Journal of Endocrinology. 2005; 152 :185-191.
16. Martina Z, Zdeněk F, Roman J, Eva K, Jiří R. Plasma cortisol in Alzheimer's disease with or without depressive symptoms. Med Sci Monit, 2013; 19: 681-689.
17. Rose EN, Adriana IL, Jose V L, Pascual AG. Effects Of Antidepressants And Soybean Association In Depressive Menopausal Women Acta Poloniae Pharmaceutica N Drug 2014; 71 (2):323-327.
18. Garg N, Singh J, Sodhi K.S, Badyal A. Evaluation Of Subclinical Hypothyroidism In Women Of Postmenopausal Age Group. Journal of Advance Researches in Biological Sciences, 2012, Vol. 4 (1) 20-22.
19. World Health Organization Scientific Group. Research on the Menopause in the 1990s.

- Geneva, Switzerland: World Health Organization; 1996. WHO Technical Report Series 866.
20. Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Utian W, Woods N. Executive summary: Stages of Reproductive Aging Workshop (STRAW). *Climacteric*. 2001; 4(4):267–272. [PubMed: 11770182].
 21. Tsigos C, Chrousos G.P. Hypothalamic–pituitary–adrenal axis, neuroendocrine factors and stress. *J. Psychosom. Res.* 2002. 53, 865–871.
 22. Van Praag HM. Crossroads of corticotropin releasing hormone, monoamines, between stress and depression. *Neurotox Res.* 2002; 4: 531–55.
 23. Nancy FW, Ellen SM, Kathleen SD. Cortisol Levels during the Menopausal Transition and Early Postmenopause: Observations from the Seattle Midlife Women's Health Study. *Menopause*. 2009; 16(4): 708–718.